ArticleCureus2026
A Rare Case of Nodal T-follicular Helper Cell Lymphoma That Developed Cutaneous Lesions With Numerous Epstein-Barr Virus-Positive T Cells.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a case of nodal T-follicular helper cell lymphoma (TFHL) in an elderly patient who developed multiple cutaneous lesions containing abundant Epstein-Barr virus (EBV)-positive neoplastic T cells. A pharyngeal mass and systemic lymphadenopathy were identified in a 78-year-old male. A histological and immunohistochemical review demonstrated diffuse and nodular infiltrates composed of small- to medium-sized atypical CD3-, CD4- and TFH cell marker-positive lymphoid cells, with scattered EBV-positive B cells and T cells. A diagnosis of nodal TFHL was made, but the patient refused chemotherapy. Indurated erythematous plaques and cutaneous nodules involving the trunk and arms developed one year and eight months after the onset of the lymph node and pharyngeal lesions. A histological examination of the skin nodule demonstrated diffuse infiltration of atypical small- to medium-sized lymphoid cells in the dermis and subcutis. Immunohistochemistry demonstrated that the atypical lymphoid cells were CD3- and CD4-positive and expressed TFH cell markers. Numerous EBV-positive cells were identified among the CD3- and CD4-positive atypical lymphoid cells. Skin lesions of EBV-positive nodal TFHL were diagnosed. The clinical course was aggressive despite chemotherapy, and the patient developed overt leukemic changes and ultimately died of the disease. This is the first reported case of EBV-positive nodal TFHL showing cutaneous lesions demonstrating intense EBV infection in CD3- and CD4-positive lymphoid cells. The presence of EBV- and CD4-positive T cells in the initial biopsy specimens and the subsequent appearance of skin lesions with numerous EBV- and CD4-positive lymphoid cells may indicate accelerated EBV infection and an aggressive phenotypic transformation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.